5-(tert-butyl)dihydrofuran-2(3H)-one | 21175-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 5-(tert-butyl)dihydrofuran-2(3H)-one
• 英文别名: 5-Tert-butyloxolan-2-one
• CAS: 21175-44-0
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: JOOOWMKNPUTDKK-UHFFFAOYSA-N

物化性质

• 沸点：
  112 °C(Press: 12 Torr)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(tert-butyl)dihydrofuran-2(3H)-one 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以75%的产率得到5-tert-Butyltetrahydrofuran-2-ol
  参考文献：
  名称：

  Schmitt, Andreas; Reissig, Hans-Ulrich, Chemische Berichte, 1995, vol. 128, # 9, p. 871 - 876

  摘要：

  DOI：
• 作为产物：
  描述：

  2-tert-Butyl-2-trimethylsilanyloxy-cyclopropanecarboxylic acid methyl ester 在 钾硼氢 作用下， 以 甲醇 为溶剂， 反应 17.0h， 以91%的产率得到5-(tert-butyl)dihydrofuran-2(3H)-one
  参考文献：
  名称：

  2-Siloxy-substituted methyl cyclopropanecarboxylates as building blocks in synthesis: efficient one-pot conversion to .gamma.-butyrolactones

  摘要：

  DOI：

  10.1021/jo00202a017

文献信息

• NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
  申请人：Ryono Denis E.

  公开号：US20080009465A1

  公开（公告）日：2008-01-10

  Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

  提供了磷酸酯和磷酸酯激活剂，因此在治疗糖尿病和相关疾病方面非常有用，并具有以下结构： 其中 是杂环芳基环； R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ； R 5 和R 6 分别选择自H、烷基和卤素； Y为R 7 (CH 2 ) s 或不存在；以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义；或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
• Lithium- α-lithioacetate and β-lithiopropionate: useful intermediates in organic synthesis
  作者：Isidro M Pastor、Miguel Yus

  DOI：10.1016/s0040-4039(00)00794-2

  日期：2000.7

  The reaction of chloroacetic acid and 3-chloropropionic acid with a base (LDA or BunLi, respectively) and then with an excess of lithium and a catalytic amount of 4,4′-di-tert-butylbiphenyl (DTBB, 5%) in the presence of different electrophiles [ButCHO, PhCHO, Et2CO, (CH2)5CO, PhCOMe] in THF at −78°C leads, after hydrolysis with water, to the expected hydroxy acids, which in the second case are directly

  氯乙酸和3-氯丙酸与碱（分别为LDA或Bu n Li）的反应，然后与过量的锂和催化量的4,4'-二叔丁基联苯（DTBB，5％）反应在不同的亲电子试剂的存在下[卜吨CHO，苯甲醛，等2 CO，（CH 2）5 CO，PhCOMe]在THF中在-78℃下引线，与水水解后，与预期的羟基酸，其中在所述第二在酸性条件下，直接将其环化，得到预期的γ-内酯。
• Ruthenium pincer-catalyzed synthesis of substituted γ-butyrolactones using hydrogen autotransfer methodology
  作者：Miguel Peña-López、Helfried Neumann、Matthias Beller

  DOI：10.1039/c5cc01708d

  日期：——

  The ruthenium pincer-catalyzed synthesis of γ-butyrolactones from 1,2-diols and malonates using borrowing-hydrogen methodology is reported.

  本文报道了使用借氢方法，通过钌夹钳催化从1,2-二醇和丙二酸酯合成γ-丁内酯的过程。

• Efficient Transfer of Chelating Amides into Different Types of Esters and Lactones
  作者：Uwe Jakob、Stephan Mundinger、Willi Bannwarth

  DOI：10.1002/ejoc.201402843

  日期：2014.11

  corresponding esters despite the fact that the former are thermodynamically more stable. The transformations are mediated by the coordination of CuI by a chelating entity. The resulting weakening of the amide bond allows for nucleophilic attack by alcoholic hydroxyl functions. The principle is demonstrated for a wide variety of transformations, leading to different kinds of esters and lactones.

  我们描述了一种将羧酸酰胺转化为其相应酯的通用方法，尽管前者在热力学上更稳定。转化是由螯合实体协调 CuI 介导的。由此产生的酰胺键弱化允许醇羟基官能团进行亲核攻击。该原理适用于各种转化，导致产生不同种类的酯和内酯。
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一系列新颖的非甾体化合物，这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用，包括炎性和免疫疾病，具有以下结构式（I）： 其对应的光学异构体、对映异构体或互变异构体，或其前药酯，或其药用可接受盐，其中： Z是杂环或杂芳基； A是一个5至8成员的碳环或一个5至8成员的杂环； B是一个环烷基、环烯基、芳基、杂环或杂芳基环，其中每个环都与A环上的相邻原子融合，并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代； J1、J2和J3每次出现时相同或不同，独立地选自-A1QA2-；Q是键、O、S、S(O)或S(O)2；A1和A2相同或不同，每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基，前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环； R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。